What caused Moderna stock to surge on May 8, and how significant is its mRNA flu vaccine data compared with the hype around its hantavirus vaccine work?

That flu data is commercially and medically significant because seasonal flu is a recurring, large vaccine market, and positive Phase 3 efficacy data can support regulatory approval and revenue diversification beyond COVID vaccines .

The hantavirus story is much less developed: Moderna said it is researching vaccines against hantaviruses, and reports describe the work as early-stage, including research with the U.S. Army Medical Research Institute of Infectious Diseases . Korea University and Moderna also reportedly began joint mRNA-based hantavirus vaccine R&D in 2023 .

Public-health experts reportedly downplayed the likelihood that the cruise-ship hantavirus incident would become a major broader threat, which makes the stock-market enthusiasm around hantavirus look more speculative than evidence-based .

In short: the mRNA flu data is the substantive catalyst because it is late-stage, peer-reviewed, and tied to a large recurring market; the hantavirus work is a headline-driven optionality story, not yet a comparable value driver.